CTOs on the Move

Karuna Pharmaceuticals

www.karunapharma.com

 
Karuna Pharmaceuticals is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Karuna Pharmaceuticals raised $42M on 07/11/2018
Karuna Pharmaceuticals raised $42M on 08/02/2018
Karuna Pharmaceuticals raised $68M on 03/18/2019
Karuna Pharmaceuticals raised $250M on 03/01/2021

Similar Companies

Medvantx

Medvantx Pharmacy Services helps pharmaceutical brands do more than just survive in an ever-changing marketplace - we help them thrive in it. Medvantx provides powerful and personalized support to healthcare partners (HCPs) and their patients. We service the specialty needs of pharmaceutical manufacturers by offering patient assistance programs and providing efficient intake solutions, nationwide dispense and fulfillment services, quality aftercare through counseling and customer service, safe and secure data handling, dependable inventory management and logistics, and insightful reporting and accounting. Serving more than 50 pharmaceutical manufacturers and managing more than $7.5 billion B of prescriptions annually, Medvantx has been redefining pharmacy for over 20 years.

Beech Brook

Helping children & families thrive by promoting healthy child development, strengthening the ability to overcome adversity, & enhancing family health & stability.

Aptalis Pharma

Aptalis Pharma is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

21st Century Biochemicals

21st Century Biochemicals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.